Sandbox/general: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 17: Line 17:
<div class="mw-customtoggle-table14" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table14" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Gram-Positive (Cocco-)Bacilli'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Newborn Conjunctivitis'''
</font>
</font>
</div>
</div>
Line 86: Line 86:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Gram-Positive (Cocco-)Bacilli}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Newborn Conjunctivitis}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | ''''' N. gonorrhoeae (after 2-5 days)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Penicillin G]] 4 MU IV q4h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 25-50 mg/kg IV x 1 dose (not to exceed 125 mg)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | ''''' C. trachomatis (after 3-10 days)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1.7 mg/kg IV q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Erythromycin]] base or ethyl succinate syrup 12.5 mg/kg q6h x 14 days'''''<BR> OR <BR> ▸ '''''[[Azithromycin ]] suspension 20 mg/kg po q24h x 3 days'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | ''''' H. simplex (after  2-16 days)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[TMP/SMZ]] 5 mg/kg IV q6—12h''''' <SMALL>(TMP component)</SMALL><BR> OR <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Acyclovir]] 60 mg/kg/day IV divided into 3 daily doses'''''<BR> OR <BR> ▸ '''''[[Trifluridine]] OR [[Vidarabine]] as a topical antiviral therapy'''''
|-
|-
|}
|}

Revision as of 19:58, 3 February 2014

▸ Click on the following categories to expand treatment regimens.

Conjunctivitis Medical Therapy

  ▸  Bacterial Conjunctivitis

  ▸  Newborn Conjunctivitis

Gram-Negative

  ▸  Gram-Negative Cocci in Pairs

  ▸  Gram-Negative Coccobacilli

  ▸  Gram-Negative Bacilli

Bacterial Conjunctivitis
Preferred Regimen
Non-gonococcal
Ciprofloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days
OR
Gatifloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days
OR
Levofloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days
OR
Moxifloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days
Gonococcal
Adult dose
Ciprofloxacin 1 gm IM/IV as 1 dose
Pediatric dose
Ciprofloxacin 25-50 mg/kg IV/IM (not to exceed 125 mg) as 1 dose
Alternative Regimen (for non-gonococcal only)
Polymyxin B + Trimethoprim 1–2 gtts q3–6h x 7–10 days
OR
Azithromycin 1%, 1 gtt bid x 2 days, then 1 gtt daily x 5 days
Chlamydia Trachomatis
Preferred Regimen
Azithromycin 1 gm once or twice weekly
Alternative Regimen
Doxycycline 100 mg bid po x 7 days
Newborn Conjunctivitis
N. gonorrhoeae (after 2-5 days)
Ceftriaxone 25-50 mg/kg IV x 1 dose (not to exceed 125 mg)
C. trachomatis (after 3-10 days)
Erythromycin base or ethyl succinate syrup 12.5 mg/kg q6h x 14 days
OR
Azithromycin suspension 20 mg/kg po q24h x 3 days
H. simplex (after 2-16 days)
Acyclovir 60 mg/kg/day IV divided into 3 daily doses
OR
Trifluridine OR Vidarabine as a topical antiviral therapy
Gram-Negative Cocci in Pairs
Preferred Regimen
Cefotaxime 2 g IV q4—6h
OR
Ceftriaxone 2 g IV q12h
Alternative Regimen
Penicillin G 4 MU IV q4h
OR
Ampicillin 2 g IV q4h
OR
Chloramphenicol 1—1.5 g IV q6h
OR
Moxifloxacin 400 mg IV q24h
OR
Aztreonam 2 g IV q6—8h
Gram-Negative Coccobacilli
Preferred Regimen
Cefotaxime 2 g IV q4—6h
OR
Ceftriaxone 2 g IV q12h
Alternative Regimen
Chloramphenicol 1—1.5 g IV q6h
OR
Cefepime 2 g IV q8h
OR
Meropenem 2 g IV q8h
OR
Moxifloxacin 400 mg IV q24h
Gram-Negative Bacilli
Preferred Regimen
Cefotaxime 2 g IV q4—6h
OR
Ceftriaxone 2 g IV q12h
Alternative Regimen
Cefepime 2 g IV q8h
OR
Meropenem 2 g IV q8h
OR
Aztreonam 2 g IV q6—8h
OR
Moxifloxacin 400 mg IV q24h
OR
TMP/SMZ 5 mg/kg IV q6—12h (TMP component)